Last reviewed · How we verify
Montelukast or equivalent — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Montelukast or equivalent (Montelukast or equivalent) — Sanofi.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Montelukast or equivalent TARGET | Montelukast or equivalent | Sanofi | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Montelukast or equivalent CI watch — RSS
- Montelukast or equivalent CI watch — Atom
- Montelukast or equivalent CI watch — JSON
- Montelukast or equivalent alone — RSS
Cite this brief
Drug Landscape (2026). Montelukast or equivalent — Competitive Intelligence Brief. https://druglandscape.com/ci/montelukast-or-equivalent. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing